CLAIM CARD
Several outcome domains within this synthesis rest on findings from a single study, meaning that replication cannot be assessed within the corpus. For example, the cardiometabolic signal in diabetic mouse models comes solely from Takemura 2025 and Sun 2025, with no independent corroboration from human trials measuring glycemic endpoints such as HbA1c against the ADA 2024 target of 7%. Similarly, the longevity signal is supported only by Su 2019 in Drosophila and Alpha-ketoglutarate 2018, also in Drosophila, with no mammalian lifespan data in the corpus. Single-trial outcomes carry heightened risk of both type I error and idiosyncratic model effects, and the synthesis accordingly assigns low confidence to claims in these domains until corroborating evidence emerges.
Evidence grade: exploratory
Contradiction status: none
Publication: 494277b2-426f-4cdc-99b0-561816dabda5
Provenance: Derivation Web chain
Citation Support
source_1Greilberger 2023source_2Greilberger 2022source_3Qiu 2025source_4Greilberger 2021source_5Wu 2022